This research will push the boundaries of current knowledge in receptor pharmacology and translate this knowledge into clinical outcomes. Receptors are proteins on the surface of our cells that bind hormones, neurotransmitters and pharmaceuticals. By better understanding the complexities of how these receptors work at the molecular level, the objective is to develop improved treatments and better clinical management for a range of medical conditions.
Defining The Roles Of The Chemotactic Receptor EBI2 For The Regulation Of Leukocyte Migration And The Generation Of Immunity
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
The proposed study aims at improving our understanding of the role of the immune cell receptor Epstein-Barr virus-induced gene 2 (EBI2) in guiding the movement of white blood cells during immune responses. The project will investigate the function of EBI2 in the control of infectious diseases and its regulation on human immune cells. These insights have the potential to create new therapeutic approaches to treat human autoimmune and inflammatory diseases and improve vaccine design.
In this fellowship I will develop methods to improve the way drugs are delivered through the use of nanotechnology. Nanoparticles can be used to protect delicate drugs from degrading, and to make sure drugs are delivered where they are required. This helps to lower side effects and improve efficacy of a range of drugs. I lead a multi-disciplinary research team dedicated to understanding of how nanoparticles interact with biological systems, so we can engineer better drug delivery systems.
Understanding Whole Cell Protein Trafficking In Plasmodium Parasites
Funder
National Health and Medical Research Council
Funding Amount
$466,492.00
Summary
I am a molecular biologist and bioinformatician studying the cell biology of human parasites. I have expertise in the bioinformatic analysis of parasite genomes to predict where proteins will reside in cell, how they participate in metabolic pathways, and how they might be suitable as targets for drugs and vaccines to control parasitic diseases. This fellowship will investigate the cell biology of Plasmodium parasites, the causative agents of malaria, using computational and biochemical tools to ....I am a molecular biologist and bioinformatician studying the cell biology of human parasites. I have expertise in the bioinformatic analysis of parasite genomes to predict where proteins will reside in cell, how they participate in metabolic pathways, and how they might be suitable as targets for drugs and vaccines to control parasitic diseases. This fellowship will investigate the cell biology of Plasmodium parasites, the causative agents of malaria, using computational and biochemical tools to characterise drug and vaccine targets.Read moreRead less
Structural And Drug Discovery Studies Of Medically Important Protein Complexes
Funder
National Health and Medical Research Council
Funding Amount
$438,577.00
Summary
My research is focused on structural studies of medically important biological systems, where specific protein complex formation contributes to human illnesses. I use X-ray crystallography to visualize the whole complex at atomic resolution as well as to determine whether binding partners have undergone changes in shape upon complex formation. This structural information then helps me in drug design with goals to either disrupt or modulate the complex.
Protein Homeostasis, Protein Aggregation And Amyotrophic Lateral Sclerosis
Funder
National Health and Medical Research Council
Funding Amount
$428,065.00
Summary
There is a desperate need for biomarkers and therapeutics for Motor Neurone Disease (MND). Mutations in a growing list of genes are implicated as a cause of MND, although the way these cause MND remains a mystery. I aim to build a uniquely positioned research team that approaches this problem from a protein centric view and incorporating strategic collaborative efforts to the understanding of the pathogenesis of MND; the longterm goal of which is translation to biomarkers and therapeutics.